New Treatment for the Reduction of LDL: Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosingand provides effective and sustained LDL-C reduction.
High levels of blood cholesterol, particularly low-density lipoproteins (LDL-C), are known to be a significant contributor to cardiovascular disease. In 2019, the FDA reviewed the application for inclisiran in treating primary hyperlipidemia in adults who have elevated LDL-C while on a maximally tolerated dose of statin therapy. Inclisiran is an injectable small interfering RNA that targets the PCSK9 protein. In contrast to statins, it requires infrequent dosing (twice per year) and provides effective and sustained LDL-C reduction in conjunction along with statins. Its prolonged effect may help alleviate medication non-compliance, one of the leading causes of failure to lower cholesterol levels. Inclisiran was FDA approved in December 2021 and is widely considered a game-changer for heart disease patients.
Latest from Today's Medical Developments
- Viant expands medical device solutions
- MIDACO’s automatic 4-pallet changer with trunnion system
- Breaking Free of the Additive Manufacturing Echo Chamber
- Boston Scientific to Acquire Cortex
- Don’t miss this month’s Manufacturing Lunch + Learn!
- Coating could make medical devices safer for patients
- How robots and cobots can work for you
- Renishaw receives Industry Partner Award
